These authors contributed equally to the study.
Introduction
The cyclin-dependent kinases (CDKs) are serineÀthreonine kinases that have a crucial role in proliferation through cell cycle. Activation of CDK4 and CDK6 through D-type cyclins (notably cyclin D1) promotes proliferation of retinoblastoma protein (Rb) to initiate transition from G1 to S phase [1] .
Randomized trials with the CDK4/6 inhibitor palbociclib have reported benefit on progression-free survival in combination with endocrine therapy, leading to its approval in patients with metastatic HR-positive/HER2-negative breast cancers [2, 3] . However, to date no predictive biomarkers of efficacy to palbociclib have been identified and the pharmacodynamics of the drug has not clearly been described.
Suppression of tumor cell proliferation determined by immunochemistry (IHC) Ki67 following 2 weeks of endocrine therapy has been shown to predict recurrence-free survival in patients with breast cancer [4] . Therefore, in vivo assessment of surrogate markers such as Ki67 in a randomized short-term preoperative study, associated with comprehensive molecular profiling could help identifying those tumors with primary resistance to palbociclib and might provide some insights on treatment-induced early biomarker changes [4, 5] .
Patients and methods
Women with histologically proven untreated early-breast cancer (EBC) candidate for upfront surgery were eligible irrespective of HR and HER2 status. Patients had adequate organ function and good performance status. As requested from French health authorities, patients with not yet operated cataract were excluded. All patients gave written informed consent before enrollment. The study was conducted according to the principles of Good Clinical Practice and the Declaration of Helsinki; approved by an institutional review board (CSET 2013 (CSET : 2016 and by a National Ethics Committee (Eudract 2013-002967-24, 25/09/2013).
In this prospective monocentric, randomized open-label phase II trial (clinicaltrials.gov, NCT02008734), patients were allocated 3 : 1 to receive either palbociclib (125 mg/day orally for 14 days until the day before the surgery) or no treatment.
Breast ultrasound imaging and clinical examination including tumor measurement were carried out at baseline and at surgery. Whole blood count was carried out in the palbociclib arm patients on day 10 61. Any adverse event and relationship to study medication were recorded and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. A dose reduction to 100 mg daily palbociclib was allowed in case of toxicity. Mandatory paraffin-embedded biopsies and frozen samples were collected at baseline and at surgery.
Statistical analyses
This study included initially two co-primary end points, each one planned to be analyzed at a two-sided 0.05 significance level, so the overall type I error is 0.10. The first primary end point was antiproliferative response, defined by a natural logarithm of percentage immunohistochemistry stained tissue Ki67 (lnKi67) of <1 at day 15. The second primary end point was a binary end point 'Senescence-associated B-galactosidase expression increase' with value of 1 if there is at least a 1-unit increase in IHC at surgery when compared with baseline, otherwise 0. Unfortunately, issues in relation with determination of senescence in tumor tissues have not been resolved and this co-primary end point was abandoned.
A total of 100 patients were to be randomized in a 3 : 1 allocation to provide a 92% power to detect a difference in the proportion of patients with antiproliferative response from 5% (control) to a 35% (intervention) using a v 2 test with a pooled variance estimation at 0.05 significance level.
Secondary end points included changes from baseline in Ki67 and safety. Exploratory analyses included determining the association between pretreatment tumor biomarkers and Ki67 and the evaluation of modifications of tumor molecular characteristics under palbociclib.
To study the effect on change from baseline in Ki67 we used the logarithmic transformation. For secondary end points, we used ANCOVA models to study the effect on change from baseline. Analyses were carried out according to the intention-to-treat principle and a two-sided significance level of 0.05. There was no correction for multiple testing for exploratory analyses, except for an FDR correction in the gene expression (GE) analysis.
Biomarkers
Estrogen, progesterone receptor and HER2 status were determined locally following ASCO/CAP guidelines [6, 7] . Tissue Ki67 was independently assessed by two pathologists following international guidelines [5] . H-Score was carried out for Rb, phospho-Rb, p16, pAKT, pER, pCDK2 and CyclinD1 (details are provided in supplementary Table S1 , available at Annals of Oncology online). To assess CCND1 amplification, we used a commercial dual color probe mix, the gene probe CCND1 (on chromosome 11q13) in green was paired with a centromeric control probe in red (11p11) (Z-2071-200, Zytovision, Germany). To declare amplification, the ASCO 2013 criteria for HER2 gene status were used [7] .
Morphologic description of tumor cells was assessed at baseline and at surgery. The presence or absence of necrosis was recorded. The presence of apoptotic cells was recorded and considered as 'positive' if there were at least 10 apoptotic cells in 3 high power fields. Tumor-infiltrating lymphocytes were scored as previously published as the presence of tertiary lymphoid structures (TLS) [8] .
Details on single raw scoring results might be made available upon request to the corresponding author.
DNA and ARN extraction and GE arrays
Snap frozen tissue fragments were stored in liquid nitrogen. Nucleic acids extractions were carried out using a combined method associating AllPrep DNA/RNA Mini kit (Qiagen, Courtaboeuf, France), and Trizol LS (ThermoFisher Scientific, Illkirch, France). Tissue samples were grinded first in RLT Plus, then put on Allprep DNA spin column to separate DNA from RNA and proteins. DNA samples were collected from columns following the manufacturer's instructions. RNA was isolated from eluates using Trizol LS, as described by Life Technologies method.
DNA and RNA concentrations were determined using Qubit (ThermoFisher Scientific) and Nanodrop (ThermoFisher Scientific). Quality of RNA-preparations was assessed using Lab-on-a-chip BioAnalyzer 2000 technology (Agilent technologies).
Activating mutations of AKT1 (exon 3; c.49G>A; E17K) and PI3KCA (exons 9 and 20) genes were identified using HRM mutation scanning followed by the Sanger sequencing analysis.
Total RNA concentration and purity were measured using a spectrophotometer (Nanodrop ND8000). RNA integrity was monitored by electrophoresis (Agilent Bioanalyzer, RNA 6000 Nano Assay). GE analysis was conducted according Affymetrix recommendations to hybridize Human Gene ST2.1 arrays. Briefly, 100 ng of total RNA (range of RIN was between 2.8 and 10, average of RIN: 7.9) was processed in parallel with an external MAQC A RNA to control robustness and reproducibility of enzymatic steps. Amplified and labeled molecules were monitor in order to hybridize arrays with 2.3 mg of labeled DNA. Raw data were processed with Expression console (Affymetrix) at the Institut Curie Genomic facility and normalized using the Plier (Probe logarithmic intensity error) algorithm.
The raw GE data from the Human Gene ST2.1 arrays are publicly available at http://microarrays.curie.fr/publications/U981-GustaveRou ssy/pop/.
Results

Patients and treatment
Between January 2014 and November 2015, 101 were randomized (supplementary Figure S1 , available at Annals of Oncology online). One patient withdrew consent after randomization leading to 100 patients: 74 assigned to the palbociclib arm and 26 to no treatment. The clinical data cut-off was January 2016.
Patients and tumor characteristics were balanced between treatment groups (supplementary Table S2 , available at Annals of Oncology online). Eighty-four patients had HR-positive/HER2-negative tumors (61 palbociclib versus 23 no treatment) and 15 patients had other subtypes (12 palbociclib versus 3 no treatment). One patient had an unknown HER2 status.
All but five patients received the scheduled palbociclib dose of 125 mg for 14 days. Among those five, one received by mistake 100 mg/day for 14 days; two patients received 125 mg/day for 13 days and two other for 11 days. Dose interruptions in these four patients were related to toxicity in two and to patients' wish in the remaining two.
Safety
Palbociclib treatment was well tolerated with no serious adverse events. Forty-four patients (59%) treated with palbociclib had at least one adverse event, 86% events being grade 1 (supplementary Table S3 , available at Annals of Oncology online). Four patients experienced grade 3 toxicity: two patients grade 3 neutropenia and two grade 3 diarrhea. Grade 3 neutropenia caused a 5-day surgical delay in one patient.
Antiproliferative activity
Paired pre-and posttreatment samples were available for 97 patients. Concerning the primary end point, palbociclib treatment led to significantly more antiproliferative responses (lnKi67 < 1) at day 15 compared with the control arm (58% versus 12%, P < 0.001, Figure 1A ). The effect was higher in HRpositive/HER2-negative tumors (n ¼ 84), with 70% of the patients who received palbociclib achieving lnKi67 < 1 versus 9% in the control arm; unlike triple negative or HER2-positive tumors (0% versus 33%, treatment by HR-positive/HER2-negative status interaction P ¼ 0.002) ( Figure 1B) .
Changes in Ki67 IHC expression from baseline were significantly different with palbociclib when compared with control [geometric mean change from baseline (95% CI), palbociclib 0.31 (0.24; 0.40), control 1.18 (0.77; 1.81), P < 0.001, supplementary Table S4, available 
Predictive value of baseline biomarkers
The predictive value of the different biomarkers is summarized in Table 1 . CCND1 was amplified in 27% (20/73) of the tumors in the palbociclib arm and in 33% (8/24) of the control arm. The presence of CCND1 amplification was not predictive of antiproliferative response to palbociclib versus control (interaction test, P ¼ 0.388).
In the HR-positive/HER2-negative subgroup assessed for PI3KCA mutation status (n ¼ 66/84), 27 tumors (36%) had a PIK3CA activating mutation. There were more mutated tumors in the palbociclib arm than in the control group (42% versus 19%). The presence of a PIK3CA mutation was not predictive of antiproliferative response of palbociclib (P ¼ 0.460).
We could only identify 2 AKT1-mutated cases, which precluded any predictive assessment.
In relation to proteins and GEs, when analyzing all patients, there was evidence suggesting that baseline cyclin D1 H-score predicted Ki67 change (interaction test, P ¼ 0.046), although we could not observe the same finding for lnKi67 at surgery (interaction test, P ¼ 0.359). None of the other tested proteins were significantly associated with palbociclib antiproliferative response versus control including Rb, phospho-Rb, p16, pAKT Ser473 , pER and pCDK2.
Matched GE data from both baseline and the surgical specimen were successfully obtained for 72 patients. In the HR-positive/ HER2-negative subgroup population (n ¼ 60), when searching for genes whose baseline expression was associated with antiproliferative effect at day 15, we could identify 51 genes with a raw interaction P < 0.01 but very high FDR values (supplementary Table S5 , available at Annals of Oncology online). Interestingly, two of these genes are CDC20 and CDK1, involved in mechanisms of regulation of the CDK pathway.
Correlation between pharmacodynamics and effect on cell proliferation Figure 2A and B displays the geometric mean values of phospho-Rb at surgery according to treatment and according to Ki67 antiproliferative response.
In the palbociclib-treated patients, changes from baseline in Ki67 correlated with changes from baseline in phospho-Rb in the whole population (Spearman rank correlation r ¼ 0.33, P ¼ 0.004) and in the HR-positive/HER2-negative subgroup (r ¼ 0.26, P ¼ 0.047), suggesting that tumors without phosphoRb decrease were more likely not to respond to palbociclib ( Figure 2C ).
Molecular adaptation
In the HR-positive/HER2-negative subgroup, we identified using microarray analyses a total of 39 genes whose changes from baseline in mRNA expression were significantly different between treatment arms, with a FDR corrected P-value <0.05. For all genes, the expression decreased under palbociclib treatment. The list of the 50 most significant genes with changes in GE expression before and after palbociclib is available in supplementary Table  S6 , available at Annals of Oncology online. The majority of these genes are involved in proliferation (such as MKI67, TOP2A, BIRC5) and cell cycle (such as PLK1, FOXM1).
Modulation of four selected genes CCND1, CCNE1, CCNE2 and CDK2 among the patients treated with palbociclib are summarized in Figure 3 according to Ki67 antiproliferative response. Interestingly, CCNE2 mRNA expression was not decreased in nonresponding tumors, as opposed to responders (P ¼ 0.006) in all patients, but not in the HR-positive/HER2-negative subgroup (P ¼ 0.43) (supplementary Table S7 , available at Annals of Oncology online).
Owing to potential cross-talk between CCND1, ER and PI3K/ AKT pathways, we determined the effect of palbociclib in pER and pAKT H-score expression as a mechanism of adaptation. We could not identify any significant increase in pAKT (P ¼ 0.925) or pER (P ¼ 0.644) associated with palbociclib when compared with no treatment (supplementary Table S8 , available at Annals of Oncology online). Similarly, we observed no effect of palbociclib on the percentage of TILs (P ¼ 0.137), the presence of TLS (P ¼ 1.00), necrosis (P ¼ 0.061) or apoptosis (P ¼ 0.235). We observed in our study a statistically significant difference in TILs between HR-positive/ Her2-negative tumors and other subtypes (Wilcoxon rank sum test with continuity correction P-value ¼0.007).
Impact on senescence
We were not able to determine b-galactosidase expression, the co-primary objective, as this was not feasible in either FFPE or frozen samples. We have not been able to find any alternative biomarker validated to be used in clinical samples, so we decided to leave it undetermined. Discussion CDK4/6 inhibitors have shown efficacy in breast cancer, particularly in combination with endocrine therapy [9] . In our study, we have assessed the pharmacodynamics effects of short-term (14 days) palbociclib treatment in patients with EBC before their planned surgical intervention and we have observed higher antiproliferative effect of palbociclib when compared with no treatment. The impact was even more pronounced in HR-positive/ HER2-negative tumors, in agreement with previously published preclinical data [10] , although the number of triple-negative and HER2-positive cases in our study is too small. As expected, palbociclib treatment was associated with a decrease in Rb phosphorylation from baseline except for some HR-positive/HER2-negative patients. Moreover, changes in Ki67 correlated with changes in phospho-Rb in the treated patients. This is consistent with data reported with abemaciclib in a smaller study (n ¼ 47) [11] and might suggest that those tumors with primary resistance to CDK4/6 inhibition do not present significant decrease of phospho-Rb at 15 days after initiation of treatment. Whole exome sequencing carried out in four of these eight tumors could not shed any light about potential molecular alterations associated with primary resistance (data not shown).
A similar smaller preoperative study assessed the pharmacodynamic activity of ribociclib and letrozole in tumor samples according to pRb changes and alterations in the expression on cyclin DeCDK4/6eINK4-Rb pathway genes from baseline to day 15. Similarly to our study, pRb levels varied between samples, and both increased and decreased pRb levels from baseline to day 15 were observed across patients. Interestingly, level of phosho-Rb was affected by estradiol level [12] . In addition, the NeoPalAna trial [13] assessed the addition of palbociclib to anastrozole as neoadjuvant therapy in 50 HR-positive/HER2-negative EBC patients. Biopsies carried out at 15 days observed significantly higher rates of Ki67 < 2% with palbociclib addition (P < 0.001) but Ki67 levels rapidly recovered after palbociclib withdrawal. This study also identified persistent elevated expression of CCND3, CCNE1 and CDKN2D at day 15 in patients resistant to palbociclib. Preclinical studies have suggested the need of an intact Rb tumor suppressor downstream of CDK4/6 for palbociclib to have an effect. It has also been inferred that tumors with deregulation of cyclin D1 by amplification or protein expression could 
For 72 patients we had GEs both at baseline and at surgery in the overall population; among these patients 60 had HRþ/HER2À BC. HR, Hormone receptor; HER2, human epidermal growth factor receptor 2.
render tumors more sensitive to CDK4/6 inhibitors due to upregulation of this pathway [10] . However, recently biomarker analyses in advanced HR-positive breast cancer patients from the phase III PALOMA-2 clinical trial [9] could not identify baseline ER, Rb, cyclin D1, p16 or Ki67 as predictive of palbociclib benefit. In our study, we were not able to identify any strong baseline predictive biomarker of the antiproliferative response to palbociclib treatment. Due to the limited sample size, the study had low statistical power for interaction tests. However, there was some suggestive evidence that cyclin D1 could be associated with the magnitude of the change in tissue Ki67 from baseline in the overall population. The potential impact of CyclinD1 at baseline in the efficacy of CDK4/6 inhibitors will need to be confirmed in a different set of patients.
Recent preclinical data have pointed out at a noncanonical cyclin D1-CDK2-mediated S-phase entry as potential escaping mechanism to CDK4/6 inhibition. We could not observe any changes in pCDK2 expression between treated and control arm, and pCDK2 levels were not predictive of palbociclib resistance. One explanation might be that 14 days treatment would be too short to activate this escaping mechanism. In addition, we could not identify CCDN1 amplification or PIK3CA mutation as predictive biomarkers of palbociclib efficacy, in agreement with findings in advanced breast cancer patients [9] . The POP clinical trial originally had senescence, determined by b-galactosidase expression, as a co-primary objective in addition to Ki67. Unfortunately, we have not been able to perform this test due to technical difficulties. No other equivalent biomarkers of senescence have been validated in IHC, leaving this co-primary objective undetermined at present.
In conclusion, this is the first randomized preoperative trial with short-term palbociclib treatment in patients with EBC. We have been able to demonstrate that 14 days of treatment are associated with extreme proliferation inhibition and decreased Rbpathway activation. This study suggests that patients without modulation of phospho-Rb by palbociclib could be the ones presenting primary resistance. Further studies will aim at identifying molecular mechanisms that lead to persistent phospho-Rb under palbociclib. 
